Literature DB >> 11910295

Does hypertension increase mortality risk from lung cancer? A prospective cohort study on smoking, hypertension and lung cancer risk among Korean men.

Soon Young Lee1, Miyong T Kim, Sun Ha Jee, Jeong Soo Im.   

Abstract

OBJECTIVE: To examine the effects of hypertension on lung cancer prospectively and to determine the interactive effect of hypertension and smoking on lung cancer risk.
DESIGN: A prospective cohort study. PARTICIPANTS: The cohort comprised 452,645 Korean men, aged 35-64 years, who received health insurance from the Korea Medical Insurance Corporation and who had biennial medical evaluations in 1992 and 1994.
METHODS: Multivariate Cox proportional hazard models were tested, controlling for age, smoking status, exercise, body mass index, alcohol use, diabetes and serum cholesterol concentration. MAIN OUTCOME MEASURE: Deaths from lung cancer.
RESULTS: At baseline, 261 080 persons (58.3%) were identified as current cigarette smokers. Between 1995 and 1999, 883 deaths from lung cancer (44.8/100,000 person-years) occurred. An initial finding indicated that hypertension increased the mortality risk of lung cancer [risk ratio (RR) 1.3, 95% confidence interval (CI) 1.1-1.5]. However, after stratification for smoking status, the risk ratio was increased only for current smokers (RR 1.4, 95% CI 1.2-1.6). When the interaction term was included in the multivariate model, there was a significant interactive effect of hypertension with current smoking (RR 1.8, 95% CI 1.0-3.1) on the risk of death from lung cancer, whereas the effect of hypertension itself did not attain significance.
CONCLUSION: Hypertension was not an independent risk factor in lung cancer-related deaths, but it increased the modest risk of lung cancer death among current smokers.

Entities:  

Mesh:

Year:  2002        PMID: 11910295     DOI: 10.1097/00004872-200204000-00017

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

1.  Analysis of the correlation among hypertension, the intake of β-blockers, and overall survival outcome in patients undergoing chemoradiotherapy with inoperable stage III non-small cell lung cancer.

Authors:  Pei Yang; Weiye Deng; Yaqian Han; Yingrui Shi; Ting Xu; Juan Shi; Hesham Elhalawani; Yu Zhao; Xiaoxue Xie; Fan Lou; Rong Zhang; Hekun Jin
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

2.  Postdiagnostic use of β-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person-years of follow-up.

Authors:  S-A Kim; H Moon; J-L Roh; S-B Kim; S-H Choi; S Y Nam; S Y Kim
Journal:  Clin Transl Oncol       Date:  2017-01-16       Impact factor: 3.405

Review 3.  Obesity, insulin resistance and cancer risk.

Authors:  Sun Ha Jee; Hee Jin Kim; Jakyoung Lee
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

4.  Smoking-associated lung cancer prevention by blockade of the beta-adrenergic receptor-mediated insulin-like growth factor receptor activation.

Authors:  Hye-Young Min; Hye-Jin Boo; Ho Jin Lee; Hyun-Ji Jang; Hye Jeong Yun; Su Jung Hwang; John Kendal Smith; Hyo-Jong Lee; Ho-Young Lee
Journal:  Oncotarget       Date:  2016-10-25

5.  Influence of Hypertension on the Survival of Non-Small Cell Lung Cancer Patients with Type 2 Diabetes Mellitus.

Authors:  Xianghua Zeng; Dong Zeng; Jianan Cheng; Cheng Xu; Chengdu Sun; Haixia Long; Bo Zhu
Journal:  Med Sci Monit       Date:  2020-04-19

6.  Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies.

Authors:  Li Qiao; Deliang Ma; Hui Lv; Ding Shi; Min Fei; Yu Chen; Fei Xie; Zhuoyan Wang; Ying Wang; Wanhua Liang; Peiying Hu
Journal:  Diabetol Metab Syndr       Date:  2020-10-28       Impact factor: 3.320

7.  Cardiovascular disease and risk of lung cancer incidence and mortality: A nationwide matched cohort study.

Authors:  Ce Wang; Donghao Lu; Deirdre Cronin-Fenton; Chen Huang; Zeyan Liew; Dang Wei; Guoyou Qin; Yongfu Yu; Jiong Li
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

8.  Noncommunicable diseases: current status of major modifiable risk factors in Korea.

Authors:  Hyeon Chang Kim; Sun Min Oh
Journal:  J Prev Med Public Health       Date:  2013-07-31

9.  Comorbidities and mortality risk among extensive-stage small-cell lung cancer patients in mainland China: impacts of hypertension, type 2 diabetes mellitus, and chronic hepatitis B virus infection.

Authors:  Weigang Xiu; Yin Huang; Yanying Li; Min Yu; Youling Gong
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.